Abstracts

grade 0 was 23 cases (33%), grade 1 was 18 cases (26%), grade 2 was 28 cases (41%). There were 16 deaths in grade 0 (69.6%), 10 deaths in grade 1 (55.6%), 15 deaths in grade 2 (53.5%). CONCLUSIONS: In this study, there was no statistically significant difference in the SWI or T2* postgroup. However, there was a tendency for many long-term survivors in the SWI or T2*-positive group.

MET-10
PRELIMINARY REPORT OF RADIOTHERAPY FOR BRAIN METASTASES FROM BREAST AND KIDNEY USING MASK SYSTEM OF LEKSELL GAMMA KNIFE ICON
Takuya Kabawe1, Manabu Sato1; 1Department of neurosurgery, Rakusai Shimizu Hospital, Kyoton, Japan

OBJECT: Leksell Gamma Knife Icon enables us to apply new methods of immobilization using mask fixation and the option of fractionated treatment. This provides exceptional accuracy and precision of radiosurgery, making it a possibility for many more disease types and many more patients to be treated.

METHODS: We retrospectively analyzed 97 patients (140 times) with brain metastases from breast (B group) and 26 patients (33 times) with brain metastases from kidney (K group) and who underwent Gamma Knife Icon using mask fixation between September 25th, 2017 and June 30th, 2020 at Rakusai Shimizu Hospital. Patients with small, few, newly diagnosed, and non-eloquent area tumors were treated in a single session. If the tumor volume was larger than 5.0 ml, recurrence, or the location was in an eloquent area, we applied a fractionated schedule. If the tumor number was large, we selected a multisession schedule. Median tumor number was three (1-64) in B group and two (1-31) in K group. Median tumor size was 2.7 (0.01-58.8) ml in B group and 2.8 (0.02-123.5) ml in K group. We selected fractionated schedules as follows: 7.0 Gy x 5Fr (5-10 ml), 4.2Gy x 10Fr (10-20ml), 3.7Gy x 10Fr (20-30ml), 3.2Gy x 10Fr (30ml-)

RESULTS: 32 (B) and 14 (K) cases were treated in a single session, 80 (B) and 28 (K) with fractionation, and 28 (B) and 2 (K) with multiple sessions. Median survival times after Icon treatment was 28.2 (B) and 15.5 (K) months. Local control rates were 89% (B) and 85% after 12-month Icon treatment. Qualitative survival rates were 91% (B) and 96% (K) after 12-month Icon treatment. There were no no statistically differences between two groups.

CONCLUSIONS: Although these results are limited to short periods, survival rates, local control rates and qualitative survival rates were within the acceptable ranges.

OTHER BRAIN TUMORS (BT)

BT-09
ANHIDROSIS IN NEUROHYPOPHYSEAL GERMINOMA TREATED WITH CBDDCA AND VP-16
Koji Adachi1, Shinichi Ansari2, Fumio Yamaguchi2, Yumi Igarashi3, Aki Mori4; 1Department of Neurosurgical Surgery, Musashi-Kosugi Hospital, Nippon Medical School, Kawasaki, Japan

INTRODUCTION: Acquired generalized anhidrosis (AGA) is the disease with no congenital, non-segmental diffuse sweating dysfunction and is associated with neurological signs and dysautonomia except for anhidrosis. Here we have experienced 2 cases of AGA in the patient with neurohypophyseal germinoma after carboplatin (CBDDCA) plus etoposide (VP-16) (CARE) therapy. Relationship of AGA to neurohypophyseal germinomas and their treatment is discussed. CASES: We experienced two young (26 y/o and 27 y/o) female neurohypophyseal germinoma cases of anhidrosis. They received CARE as chemotherapy and whole ventricular irradiation. They showed heat retention 2 to 3 years after initial treatment without recurring germinoma. Because acetylcholine sweating test was negative and skin biopsy revealed normal sweat gland structure, the diagnosis of acquired idiopathic autonomic dysfunction (AGA) was rooted. Partial resection of the failure supratentorial mass was initially made. After steroid pulse therapy, sweat function recovered partially.

We present a case of a 14-year old boy with tumor-associated refractory epilepsy. Posterior emission tomography imaging demonstrated a region with homogeneous low 11 C-methionine uptake and a region with homogenous low 18 F- fluorodeoxyglucose uptake within the tumor. Histopathologic and genomic analyses confirmed the tumor as BRAF V600E-mutated PLNTY (polymorphic low-grade neuroepithelial tumor of the young). Within the high-methionine-uptake region, we observed increased protein levels of L-type amino acid transporter 1 (LAT1) and constituents of the mitogen-activated protein kinase (MAPK) pathway. We also found that LAT1 expression was linked to BRAF V600E mutation and subsequent activation of MAPK signaling. Pharmacological inhibition of the MAPK pathway suppressed LAT1 expression and cell viability in PLNTY cells. Collectively, our results indicate that BRAF V600E mutation-activated MAPK signaling induces specific metabolic alterations in PLNTY, and may represent an attractive target in the treatment of the disease.

CS-03
BRAF V600E MUTATION MEDIATES FDG-METHIONINE UPTAKE MISMATCH IN POLYMORPHIC LOW-GRADE NEUROEPITHELIAL TUMOR OF THE YOUNG
Takahiro Hayashi1, Kensuke Tateshi2, Naoki Ikeyama1, Naoko Udaka1, Jo Sasame1, Yohei Miyake1, Tetsuhiko Okabe1, Ryogo Minamamoto1, Hidetoshi Murata2, Daisuke Utsunomiy2, Syoji Yamakawa3, Tetsuya Yamamoto3; 1The Department of Neurosurgery, Yokohama City University, Kanagawa, Japan

We present a case of a 14-year old boy with tumor-associated refractory epilepsy. Posterior emission tomography imaging demonstrated a region with homogeneous low 11 C-methionine uptake and a region with homogenous low 18 F- fluorodeoxyglucose uptake within the tumor. Histopathologic and genomic analyses confirmed the tumor as BRAF V600E-mutated PLNTY (polymorphic low-grade neuroepithelial tumor of the young). Within the high-methionine-uptake region, we observed increased protein levels of L-type amino acid transporter 1 (LAT1) and constituents of the mitogen-activated protein kinase (MAPK) pathway. We also found that LAT1 expression was linked to BRAF V600E mutation and subsequent activation of MAPK signaling. Pharmacological inhibition of the MAPK pathway suppressed LAT1 expression and cell viability in PLNTY cells. Collectively, our results indicate that BRAF V600E mutation-activated MAPK signaling induces specific metabolic alterations in PLNTY, and may represent an attractive target in the treatment of the disease.

CS-09
EXTRA-PARENCYHMAL (PERIPHERAL) ATYPICAL TERATOID / RHABDOID TUMORS
Hidehiro Oka1, Mari Kusumi1, Masafumi Koremura2, Koji Kondo3; 1Department of Neurosurgery, Kitasato University Medical Center, Kitamoto, Japan

AT/RT is a malignant embryonal tumor reported by Rorke in 1996. Authors reported first AT/RT in Japan in 1998. This tumor entity was included as new malignant embryonal tumor in WHO 2000, and tumors of Japanese patients has been reported more than 80 cases in the past. This AT/RT is a tumor in the brain parenchyma that a medulloblastoma and PNET and the possibility that it has been misdiagnosed have had pointed out. On the other hand, it is reported that there is the type that we should call peripheral AT/RT which rarely occurs in extra-parenchyma. We want to propose that there is such special tumor group. In the results, age: 17 infants were